Finzati - Logo
CPRX logo

Catalyst Pharmaceuticals, Inc.

CPRX • Biotechnology
$31.49
— 0.00 (0.00%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$4.00B
Growth
—
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 36.4%Positive revenue growth · 37.1%Positive free cash flow · 1.71Consistent free cash flow · 5/5Reasonable earnings multiple · 13.32
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 11, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 1:54 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$31.49
Change0.00%
Shares Out126.90M
Market Cap$4.00B
Enterprise Value$3.24B
52W Range19.05 - 32.56
Beta0.74
P/E18.06
P/S6.69
P/B3.95
P/FCF19.20
EV/Sales5.43

Investment DNA

How strong this company looks for long-term investors

87
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
80/100
Why this score▼
Stable or improving margins · 36.4%Positive revenue growth · 37.1%Positive free cash flow · 1.71Consistent free cash flow · 5/5Reasonable earnings multiple · 13.32Manageable debt level · 0

Analyst view

Analyst sentiment and price target

CPRX
Analyst sentiment
Based on 16 analyst votes · 2026-09-05
88/100
Bullish
Bullish
12
Hold
4
Bearish
0
Price Target
2026-08-06
Low
$31.50
Mean
$31.75
Median
$31.75
High
$32.00

Company Overview

IPO: 11/8/2006
Industry: Biotechnology
P/B i: 3.95
Debt / Equity i: 0.00
Operating Margin: 43.77%
Net Margin: 36.39%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.00
Current Ratio: 6.08
Quick Ratio: 5.82
Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 6 high-volume insider sells detected
Kalb Michael Wayne
Transaction: 07/15/2026
SELL
Change
-39,701
Price
Not reported
Filing
07/17/2026
Type
SELL
Kalb Michael Wayne
Transaction: 07/15/2026
SELL
Change
-131,536
Price
$22.77
Filing
07/17/2026
Type
SELL
Kalb Michael Wayne
Transaction: 07/15/2026
SELL
Change
-13,665
Price
$31.50
Filing
07/17/2026
Type
SELL